Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma

Archives of Dermatology

Volumn 137, Issue 9, 2001, Pages 1217-1224

  Dubois, Robert W ^a   Swetter, Susan M ^b,c   Atkins, Michael ^d   McMasters, Kelly ^e   Halbert, Ron ^a   Miller, Stanley J ^f   Shiell, Ronald ^g   Kirkwood, John ^h  

^a Protocare Sciences Inc   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC PROCEDURE; DRUG INDICATION; EVIDENCE BASED MEDICINE; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; TREATMENT INDICATION;

EID: 0034849915     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.137.9.1217     Document Type: Article

References (30)

1. Sentinel lymph node biopsy in cutaneous melanoma: The WHO melanoma program experience
2. Review of sentinel lymph node biopsy and systemic interferon for melanoma: Promising but investigational modalities
3. A new American joint committee on cancer staging system for cutaneous melanoma
4. Physician ratings of appropriate indications for six medical and surgical procedures
5. Relapse-free and overall survival are significantly prolonged by high-dose IFNα2b (HDFI) compared to vaccine GM2-KLH with QS21 (GMK, Progenics) for high-risk resected stage I/B-III melanoma: Results of the intergroup Phase III study E1694/S9512/C509801
6. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial
7. Initial results of a multicenter trial of lymphatic mapping and sentinel lymphadenectomy for primary melanoma
8. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients
9. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma
10. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
11. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma
12. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
13. Sentinel node biopsy for melanoma in the head and neck region
14. Reliability of sentinel lymph node biopsy for staging melanoma
15. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes
16. Molecular staging of malignant melanoma: Correlation with clinical outcome
17. Sentinel node biopsy and selective dissection for melanoma nodal metastases
18. Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients
19. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma
20. Towards quality assurance of the sentinel node procedure in malignant melanoma patients: A single institution evaluation and a European survey
21. Management of malignant melanoma of the head and neck using dynamic lymphoscintigraphy and gamma probe-guided sentinel lymph node biopsy
22. Adjuvant IFN alfa 2 therapy of melanoma
23. Results of adjuvant interferon study in WHO melanoma programme
24. Evaluation of efficacy of adjuvant rIFNalfa-2a in melanoma patients with regional node metastases
25. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
26. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
27. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/09190
28. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
29. Toxicity of adjuvant high-dose interferon-alpha-2b inpatients with cutaneous melanoma at high risk of recurrence